百心安-B：2023年報

Futu NewsApr 26 18:32 · Announcements

OrbiMed Capital LLC sold 1,548,600 H shares of Baixinan-B (02185.HK) worth approximately HK$3.7941 million

On March 26, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 26, OrbiMed Capital LLC sold $1,548,600 H shares worth HK$3.7941 million at an average price of HK$2.45 per share on March 22. After the sale, OrbiMed Capital LLC's latest shareholding was 11.3564 million shares, and the good position ratio dropped from 5.46% to 4.81%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange,

Futu NewsMar 26 17:02

Baixinan-B (02185.HK) lost about 189 million yuan in 2023

Gelonghui, March 25 | Baixinan-B (02185.HK) announced that for the year ended December 31, 2023, the Group's net loss was approximately RMB 188.8 million, a decrease of 18.2% from approximately RMB 230.9 million in 2022. R&D expenditure for the year ended 31 December 2023 was approximately RMB 111.7 million, a decrease of 29.2% from approximately RMB 157.8 million recorded in 2022. As of December 31, 2023, the net asset liability ratio was 5.4% (2022:6.8%).

Gelonghui FinanceMar 25 22:25

BIOHEART-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

Futu NewsMar 25 22:21 · Announcements

Baixinan-B (02185.HK) plans to hold a board meeting on March 25 to approve the annual results

Gelonghui, March 13 | Baixinan-B (02185.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).

Gelonghui FinanceMar 13 16:33

BIOHEART-B: DATE OF BOARD MEETING

Futu NewsMar 13 16:30 · Announcements